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48.7% of the males and 52.0% of the females (p = 0.29)
were prescribed drug therapy within a year of diagnosis.
Median time to treatment was 436 (95% Cd, 289, 774)
and 318 (95% c.l. 176,518) days for men and women,
respectively.
CONCLUSIONS: In terms of both rate of drug therapy
initiation and time to treatment for lipid disorders, our
study showed no statistically significant difference be-
tween men and women.
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The "statin" market is highly competitive, with primary dif-
ferences being lipid-lowering ability and acquisition cost.
Health care decision makers must be able to demonstrate
and compare the clinical and economic value of each statin.
To date, the best available data for such comparisons come
from the long-term studies 4S, CARE, and WOSCOPS.
OBJECTIVE: Lipobay, a potent new statin, was recently
introduced in Europe and will be introduced in the
United States as Baycol this year. Our objective was to
model the clinical and economic results of 4S to compare
the cost-efficiency of Lipobay to other statins.
METHODS: Our research was based on the following
assumptions: lipid-lowering ability and acquisition cost
are the only distinctions among statins; a positive linear
relationship exists between reduced lipids and reduced
cardiovascular costs; all statins, based on efficacy and
cost, can be incorporated into this relationship. Using
these assumptions, we extracted numeric data points for
cardiac hospitalization cost in 4S and developed a linear
equation, incorporating efficacy and drug cost, to esti-
mate total cost for each statin. Our cost-efficiency mea-
surement consisted of an index calculated by dividing es-
timated annual per patient total cost or drug cost in
Deutchmarks by unit reduction in LDL. This measure-
ment is interpreted as the cost per unit reduction in LDL.
Drugs whose total and drug cost indices had negative or
zero slopes when graphed and low indices were consid-
ered cost-efficient.
RESULTS: Lipobay presented a negative slope for the to-
tal cost indices and a zero slope for drug cost indices.
When comparing actual cost indices for all drugs, Lipobay
was generally within mid-range (total cost: DM98-
DM149; drug cost: DMI4).
CONCLUSION: Lipobay is cost-efficient when com-




PHARMACEUTICAL COSTS OF PATIENT
NON-ADHERENCE TO LIPID-LOWERING
DRUG THERAPY
Beck P', Downey W', Butler-Jones DI, L Lueck?
'Saskatchewan Health, Regina, Canada; 2GDS & Associates,
Regina, Canada
Lipid-lowering (LL) drugs decrease morbidity and mor-
tality due to coronary heart disease (CHD). Among CHD
patients, some LL drugs also decrease overall mortality.
To realize the therapeutic benefits, LLdrugs must be used
for at least two years. A previous study in Saskatchewan
showed that patient adherence to LLdrugs is poor.
OBJECTIVES: The objective of this study is to quantify
the direct costs of non-adherence to LL drug therapy. The
first phase will focus on pharmaceutical costs. Subse-
quent analyses will include physician services and hospi-
talization costs.
METHODS: The government of Saskatchewan maintains
comprehensive, linkable databases on health services pro-
vided to the population of approximately one million res-
idents. Eligible beneficiaries with one or more outpatient
prescriptions for LL drugs between 1989 and 1996 were
identified. Exposure time was calculated for each subject.
Cost analyses were conducted from the societal perspec-
tive.
RESULTS: LL drugs were commonly used in Saskatchewan
during the study period: 629,728 prescriptions for LL
drugs were dispensed to 32,758 people (approximately
3% of the population). Statins were the most widely used
LL drugs, followed by gemfibrozil and cholestyramine.
On average, subjects were exposed to LL drugs for 1.7
years. Only 35% of LL drug users were exposed for two
years or longer. The total cost of LL prescriptions during
the study period was $44.6 million CAN. However, $6.9
million (15%) of these costs were for prescriptions dis-
pensed to people who used LL drugs for less than two
years.
DISCUSSION: Poor patient adherence to LL drugs re-
sults in substantial wastage of pharmaceutical expendi-
tures. Future analyses will focus on outcomes associated
with non-adherence and their impact on overall physician
service, hospitalization and drug costs.
PCW.
DEVELOPMENT OF A DECISION·ANALYTIC
MODEL OF STROKE CARE IN US AND EUROPE
Chambers MI, Koch p2, Hutton J'
IMEDTAP lnternational lnc., London, UK; 2Boehringer
Ingelheim GmbH, Ingelheim, Germany
There are currently rapid developments in our ability to
offer effective preventive and therapeutic interventions
for sufferers of stroke. Concurrent pressure on national
and local health care budgets demands that new interven-
tions be evaluated for their cost-effectiveness before their
widespread implementation. Clinical trials are of rela-
